Nomic Bio, a Montréal, Canada-based protein profiling company, raised $42M in Series B funding.
The round was led by an undisclosed life-sciences-focused investor with participation from new and existing investors, including Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Milad Dagher, Nomic is improving proteomics, empowering over 75 companies—spanning top-10 pharma, biotechs, and research institutes. Together, they’ve collectively profiled more than 400,000 samples. In response to surging demand, Nomic has built industrial-scale facilities empowered by its nELISA platform, offering customers a protein profiling service. It is rapidly expanding its biological footprint to cover proteins across the entire proteome, unlocking new possibilities for diverse applications, uses cases, and disease areas.
FinSMEs
17/09/2024